Tables
- Table 1.
A large proportion of tumor cells can sustain the growth of murine lymphoid and myeloid malignancies. Cells from primary Eμ-myc pre-B/B lymphomas, Eμ-N-RAS thymic lymphomas, or PU.1–/– AML, all from mice on a C57BL/6 (Ly5.2+) background (>15 backcrosses), were transplanted into nonirradiated congenic C57BL/6 (Ly5.1+) recipient mice. To circumvent problems associated with injection of low cell numbers, we mixed the tumor cells with 106 congenic (C57BL/6-Ly5.1+) spleen cells as carriers. Shown are the fraction of recipients that developed tumors and the average time from transplantation to tumor development. No mice (0/24) injected with carrier spleen cells alone developed any tumor over a 100-day period. ND, not determined.
Recipients that developed tumors (days to kill) 105 cells 103 cells 102 cells 10 cells Eμ-myc B lymphoma Case 1 3/3 (25) 3/3 (25) 3/3 (32) 2/2 (35) Case 2 3/3 (21) 3/3 (23) 3/3 (24) 3/3 (24) Case 3 Sca-1+ AA4.1hi 3/3 (21) 3/3 (21) ND 3/3 (17) Sca-1+ AA4.1lo 2/2 (17) 2/2 (28) 2/2 (28) 2/2 (40) Eμ-N-RAS T lymphoma Case 1 3/3 (28) 3/3 (42) 3/3 (28) 3/3 (28) PU.1-/- AML Case 1 1/1 (54) 2/2 (168) 1/2 (192) 0/2 Case 2 2/2 (84) 2/2 (85) 2/2 (224) 1/2 (114) Case 3 1/1 (85) 2/2 (62) 2/2 (69) 2/2 (90) Case 4 1/1 (30) 1/1 (37) 2/2 (79) 2/2 (88)
Additional Files
Tumor Growth Need Not Be Driven by Rare Cancer Stem Cells
Priscilla N. Kelly, Aleksandar Dakic, Jerry M. Adams, Stephen L. Nutt, Andreas StrasserSupporting Online Material
This supplement contains:
Materials and Methods
Figs. S1 and S2
ReferencesThis file is in Adobe Acrobat PDF format.
